ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - metformin hydrochloride, quantity: 500 mg - tablet, modified release - excipient ingredients: carmellose sodium; copovidone; magnesium stearate; hypromellose; microcrystalline cellulose - metformin is indicated in the treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control. metformin hcl extended release tablets may be used as monotherapy or in combination with other oral antidiabetic agents, or with insulin

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - metformin hydrochloride, quantity: 750 mg - tablet, modified release - excipient ingredients: magnesium stearate; microcrystalline cellulose; hypromellose; carmellose sodium; copovidone - metformin is indicated in the treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control. metformin hcl extended release tablets may be used as monotherapy or in combination with other oral antidiabetic agents, or with insulin

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - metformin hydrochloride, quantity: 750 mg - tablet, modified release - excipient ingredients: carmellose sodium; magnesium stearate; microcrystalline cellulose; copovidone; hypromellose - metformin is indicated in the treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control. metformin hcl extended release tablets may be used as monotherapy or in combination with other oral antidiabetic agents, or with insulin

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - metformin hydrochloride, quantity: 1000 mg - tablet, modified release - excipient ingredients: microcrystalline cellulose; povidone; hypromellose; carmellose sodium; copovidone; magnesium stearate - metformin is indicated in the treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control. metformin hcl extended release tablets may be used as monotherapy or in combination with other oral antidiabetic agents, or with insulin

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - metformin hydrochloride, quantity: 1000 mg - tablet, modified release - excipient ingredients: microcrystalline cellulose; hypromellose; carmellose sodium; magnesium stearate; copovidone - metformin is indicated in the treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control. metformin hcl extended release tablets may be used as monotherapy or in combination with other oral antidiabetic agents, or with insulin

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - metformin hydrochloride, quantity: 500 mg - tablet, modified release - excipient ingredients: carmellose sodium; hypromellose; microcrystalline cellulose; magnesium stearate; copovidone - metformin is indicated in the treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control. metformin hcl extended release tablets may be used as monotherapy or in combination with other oral antidiabetic agents, or with insulin

न्यूज़ीलैंड - अंग्रेज़ी - Medsafe (Medicines Safety Authority)

astrazeneca limited - terbutaline sulfate 0.25mg; terbutaline sulfate 200ug equivalent to 0.25 mg metered dose - powder for inhalation - 0.25 mg/dose - active: terbutaline sulfate 0.25mg terbutaline sulfate 200ug equivalent to 0.25 mg metered dose excipient: lactose monohydrate - relief of bronchospasm occurring in bronchial asthma, bronchitis and other bronchopulmonary conditions where bronchospasm is a complicating factor. acute prophylaxis in situations known to induce bronchospasm, e.g. exercise induced asthma.

न्यूज़ीलैंड - अंग्रेज़ी - Medsafe (Medicines Safety Authority)

astrazeneca limited - terbutaline sulfate 0.5mg - powder for inhalation - 0.5 mg/dose - active: terbutaline sulfate 0.5mg

इसराइल - अंग्रेज़ी - Ministry of Health

vitamed pharmaceutical industries ltd - terbutaline sulfate - solution for inhalation - terbutaline sulfate 150 mg / 15 ml - terbutaline - terbutaline - bronchodilator for the treatment of acute attacks of asthma.

इसराइल - अंग्रेज़ी - Ministry of Health

vitamed pharmaceutical industries ltd - terbutaline sulfate - syrup - terbutaline sulfate 30 mg / 100 ml - terbutaline - terbutaline - bronchodilator for the treatment of acute attacks of asthma.